Clinical Trials

Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Ranging Study of Piromelatine in Patients with Mild Dementia Due to Alzheimer’s Disease (NEUP11-AD2)

The purpose of this research study is to determine an effective dose of the study drug based on results of safety and efficacy on patients with mild dementia due to Alzheimer's disease as compared to placebo


To pre-qualify for this study, a patient must:
• Be 60 to 85 years of age
• Be diagnosed with mild dementia due to Alzheimer’s disease and experienced a cognitive decline over at least 6 months
• Not have an alternative cause for dementia other than Alzheimer’s disease
• Have a permanent caregiver, who stays under the same roof at least 3 nights a week




PI: Steven Dubovsky, MD

Contact Information

Name: Sevie Kandefer
Phone: 716-898-4038